Leipzig. The biopharmaceutical company BlackSwan Pharma GmbH, dedicated to the profiling and pre-clinical development of novel agents for the treatment of haematological cancers, announced today that its consulting team has been further strengthened by the appointment of Dr. Ulrich Granzer. The inclusion of Dr. Granzer into the team highlights the wealth of experience being gathered by BlackSwan Pharma GmbH to drive their development of CD-160130.

Dr. Ulrich Granzer, the founder of Granzer Regulatory Consulting & Services, graduated as a pharmacist in 1984. During his time as a lecturer for pharmaceutical chemistry at the University of Tübingen he became a PhD in pharmaceutical chemistry (1988).
In 1989 Dr. Granzer joined Glaxo/Glaxo Wellcome Regulatory Affairs where he was appointed Director of Regulatory Affairs in 1993. Since then, he served as a member of Glaxo's and then Glaxo Wellcome's Global Regulatory Board. During this time he was also the project leader for a company wide re-engineering at Glaxo Germany.
In 1998 Dr. Granzer joined BASF Pharma as Vice President of Global Regulatory Centres, comprising global responsibility for Regulatory Affairs, Drug Safety, and GXP in development
Three years later he joined Bayer as Vice President Global Regulatory Affairs taking over responsibility for all regulatory aspects of development and submission projects worldwide
At the beginning of 2002 Ulrich Granzer decided to start his own business and became an independent consultant.
In 2007, he already was consultant for the team at Curacyte Discovery GmbH responsible for CD-160130 to attain its Orphan Drug Designation from the European Commission.
The technological base BlackSwan Pharma has been obtained through an exclusive and worldwide agreement with The Medicines Company (Leipzig) GmbH whereby both patent rights and scientific Know-How for the development of a novel series of small molecule apoptosis promoters has been agreed. The lead product, CD-160130, has received an Orphan Drug Designation from the European Commission.